Connection

YOSHIO YAMAOKA to Proton Pump Inhibitors

This is a "connection" page, showing publications YOSHIO YAMAOKA has written about Proton Pump Inhibitors.
Connection Strength

3.396
  1. CYP2C19 genotype-guided dosing of proton pump inhibitors: progress in clinical trials and real-world use. Expert Rev Clin Pharmacol. 2026 Jan-Feb; 19(2):133-150.
    View in: PubMed
    Score: 0.776
  2. Comparative efficacy, safety and compliance with dual, triple and quadruple therapy as the first-line treatment regimens for Helicobacter pylori eradication: a systematic review and network meta-analysis. BMJ Open Gastroenterol. 2026 Jan 14; 13(1).
    View in: PubMed
    Score: 0.772
  3. Appropriate first-line regimens to combat Helicobacter pylori antibiotic resistance: an Asian perspective. Molecules. 2015 Apr 08; 20(4):6068-92.
    View in: PubMed
    Score: 0.366
  4. Strategy for the treatment of Helicobacter pylori infection. Curr Pharm Des. 2014; 20(28):4489-500.
    View in: PubMed
    Score: 0.335
  5. Influence of inflammatory cytokine polymorphisms on eradication rates of Helicobacter pylori. J Gastroenterol Hepatol. 2009 Nov; 24(11):1725-32.
    View in: PubMed
    Score: 0.251
  6. Therapy for Helicobacter pylori infection can be improved: sequential therapy and beyond. Drugs. 2008; 68(6):725-36.
    View in: PubMed
    Score: 0.221
  7. Management of Antibiotic-Resistant Helicobacter pylori Infection: Perspectives from Vietnam. Gut Liver. 2019 09 15; 13(5):483-497.
    View in: PubMed
    Score: 0.124
  8. An East-Asian-type cagA Helicobacter pylori Infected Patient with Clinical Manifestation of Gastric Ulcer. Acta Med Indones. 2016 Oct; 48(4):307-313.
    View in: PubMed
    Score: 0.101
  9. Helicobacter pylori infection in Japan. Expert Rev Gastroenterol Hepatol. 2013 Jan; 7(1):35-40.
    View in: PubMed
    Score: 0.078
  10. Association of helicobacter pylori dupA with the failure of primary eradication. J Clin Gastroenterol. 2012 Apr; 46(4):297-301.
    View in: PubMed
    Score: 0.074
  11. Efficacy of fourteen-day once-daily vonoprazan-based quadruple therapy for Helicobacter pylori in high clarithromycin-resistance regions (ONCE-VONO Trial). Sci Rep. 2025 Dec 18; 15(1):44105.
    View in: PubMed
    Score: 0.048
  12. A prospective randomized trial of esomeprazole- versus pantoprazole-based triple therapy for Helicobacter pylori eradication. Am J Gastroenterol. 2005 Nov; 100(11):2387-92.
    View in: PubMed
    Score: 0.048
  13. Efficacy of Bismuth Quadruple Therapy in the Treatment of Helicobacter pylori-Infected Peptic Ulcer Children in Vietnam. Helicobacter. 2024 Nov-Dec; 29(6):e13149.
    View in: PubMed
    Score: 0.044
  14. Hybrid, High-Dose Dual and Bismuth Quadruple Therapies for First-Line Treatment of Helicobacter pylori Infection in Taiwan: A Multicenter, Open-Label, Randomized Trial. Am J Gastroenterol. 2023 07 01; 118(7):1184-1195.
    View in: PubMed
    Score: 0.040
  15. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther. 2003 Jan; 17(2):193-200.
    View in: PubMed
    Score: 0.039
  16. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020 12; 69(12):2093-2112.
    View in: PubMed
    Score: 0.033
  17. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018 Jan; 33(1):37-56.
    View in: PubMed
    Score: 0.028
  18. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol. 2003 May; 98(5):1005-9.
    View in: PubMed
    Score: 0.010
  19. Analysis of the 13C-urea breath test for detection of Helicobacter pylori infection based on the kinetics of delta-13CO2 using laser spectroscopy. J Gastroenterol Hepatol. 1998 Jul; 13(7):732-7.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.